American Oncology Network, Inc. Price & Performance (AONC)

The Oncology Institute reported a 16.9% increase in Q4 2024 revenue, reaching $100 million, driven by dispensary growth. However, patient services revenue fell due to a lost contract. Net losses narrowed to $13.2 million from $18.8 million in Q4 2023, reflecting operational efficiencies and reduced SG&A expenses.1

Lucid Diagnostics' EsoGuard DNA Test gained recognition in NCCN guidelines as a non-invasive alternative for esophageal precancer detection. This marks a milestone in expanding insurance coverage and market access, aligning with gastroenterology standards. The development may significantly enhance early cancer detection efforts.2

Woodlands Cancer Institute has relocated its clinic in The Woodlands, Texas, offering expanded patient services. The new facility includes private exam rooms, infusion rooms, and an in-house specialty pharmacy. This move aims to improve patient care, increase capacity, and provide a more comprehensive treatment environment.3